Added to the Lineup

Quest Diagnostics has a new molecular test panel to help doctors differentiate between cancerous and non-cancerous thyroid glands, the company says in a statement. The panel tests for mutations in BRAF, RAS, RET/PTC, and PAX8/PPAR gamma, which are linked to papillary and follicular thyroid cancer. "We believe our molecular panel will enhance the reliability of thyroid biopsy testing, helping to prevent the unnecessary removal of healthy thyroids for many patients," says Quest Diagnostics' Richard Reitz.

"The launch of the thyroid test comes on the heels of four new test panels introduced last month for congenital adrenal hyperplasia, an endocrine disorder mostly found in newborns, children, and women," notes Zacks Equity Research.